Payment overview · 2025
General Payments
$742.49
38 reported records · 13 companies
Healthcare provider profile · identity verified
Gregory A Dean, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BETHANY, MO · NPI 1568430437
Verified facts
What the public records show
CMS Open Payments records show Gregory A Dean, M.D. received $742.49 in general payments during 2025 across 38 reported records.
Novo Nordisk Inc accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $160.28 | 21.6% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $141.36 | 19.0% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $101.40 | 13.7% | 6 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $55.72 | 7.5% | 3 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $54.87 | 7.4% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $35.35 | 4.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $34.50 | 4.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.39 | 4.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.88 | 4.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.46 | 4.1% | 2 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $26.36 | 3.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.96 | 2.5% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $14.96 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $742.49 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $141.36 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $87.34 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $87.34 | 5 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $55.72 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $35.35 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $34.50 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.39 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.46 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.90 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 128 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 82 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
128 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 758 | 133 |
| Potassium Chloride | Potassium Chloride | 542 | 126 |
| Furosemide | Furosemide | 469 | 104 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 422 | 69 |
| Atorvastatin Calcium | Atorvastatin Calcium | 421 | 105 |
| Lisinopril | Lisinopril | 406 | 100 |
| Gabapentin | Gabapentin | 383 | 78 |
| Omeprazole | Omeprazole | 374 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 373 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 352 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 351 | 98 |
| Metoprolol Tartrate | Metoprolol Tartrate | 313 | 77 |
| Metformin Hcl | Metformin Hcl | 271 | 62 |
| Losartan Potassium | Losartan Potassium | 247 | 62 |
| Sertraline Hcl | Sertraline Hcl | 242 | 49 |
| Ezetimibe | Ezetimibe | 240 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 238 | 62 |
| Alprazolam | Alprazolam | 209 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 46 |
| Tramadol Hcl | Tramadol Hcl | 199 | 45 |
| Meloxicam | Meloxicam | 198 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 186 | 48 |
| Doxycycline Hyclate | Doxycycline Hyclate | 170 | 112 |
| Tizanidine Hcl | Tizanidine Hcl | 149 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 53 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 140 | 20 |
| Methylprednisolone | Methylprednisolone | 140 | 104 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 135 | 22 |
| Montelukast Sodium | Montelukast Sodium | 130 | 31 |
| Eliquis | Apixaban | 128 | 22 |
| Warfarin Sodium | Warfarin Sodium | 126 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 125 | 70 |
| Buspirone Hcl | Buspirone Hcl | 125 | 19 |
| Trazodone Hcl | Trazodone Hcl | 123 | 24 |
| Methocarbamol | Methocarbamol | 120 | 35 |
| Prednisone | Prednisone | 120 | 51 |
| Carvedilol | Carvedilol | 118 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 26 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 104 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 103 | 19 |
| Spironolactone | Spironolactone | 98 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 14 |
| Pregabalin | Pregabalin | 90 | 16 |
| Repatha Sureclick | Evolocumab | 88 | suppressed |
| Cephalexin | Cephalexin | 87 | 56 |
| Nystatin | Nystatin | 85 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 17 |
| Ondansetron Odt | Ondansetron | 84 | 24 |
| Simvastatin | Simvastatin | 84 | 25 |
| Jardiance | Empagliflozin | 82 | 16 |
| Donepezil Hcl | Donepezil Hcl | 81 | 14 |
| Azithromycin | Azithromycin | 77 | 65 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 77 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 73 | 15 |
| Clonazepam | Clonazepam | 73 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 20 |
| Mupirocin | Mupirocin | 71 | 48 |
| Lorazepam | Lorazepam | 68 | suppressed |
| Allopurinol | Allopurinol | 67 | 16 |
| Famotidine | Famotidine | 67 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 67 | 15 |
| Ozempic | Semaglutide | 65 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 62 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 61 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | suppressed |
| Memantine Hcl | Memantine Hcl | 54 | 12 |
| Novolog Flexpen | Insulin Aspart | 53 | 13 |
| Januvia | Sitagliptin Phosphate | 52 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 50 | 12 |
| Praluent Pen | Alirocumab | 49 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | suppressed |
| Glimepiride | Glimepiride | 48 | 14 |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Mirtazapine | Mirtazapine | 48 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 47 | 14 |
| Baclofen | Baclofen | 47 | suppressed |
| Glipizide | Glipizide | 47 | suppressed |
| Torsemide | Torsemide | 47 | 11 |
| Ciclopirox | Ciclopirox Olamine | 45 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 12 |
| Tradjenta | Linagliptin | 44 | suppressed |
| Irbesartan | Irbesartan | 42 | suppressed |
| Vascepa | Icosapent Ethyl | 41 | suppressed |
| Hydrocortisone | Hydrocortisone | 39 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 39 | suppressed |
| Oxycontin | Oxycodone Hcl | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 11 |
| Diazepam | Diazepam | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 11 |
| Hydromorphone Hcl | Hydromorphone Hcl | 33 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 21 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 28 | suppressed |
| Carisoprodol | Carisoprodol | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 21 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 21 |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Felodipine Er | Felodipine | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 18 |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | 13 |
| Temazepam | Temazepam | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 17 |
| Lumigan | Bimatoprost | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 20 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | 12 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 16 | suppressed |
| Hydromorphone Er | Hydromorphone Hcl | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | 11 |
| Risperidone | Risperidone | 16 | suppressed |
| Trimethoprim | Trimethoprim | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Fondaparinux Sodium | Fondaparinux Sodium | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydroxyurea | Hydroxyurea | 14 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Norethindrone | Norethindrone | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | 12 |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Valproic Acid | Valproic Acid | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $742.49 · 38 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, COMIRNATY, ELIQUIS, EVENITY, JARDIANCE, JOURNAVX, Kerecis GraftGuide, Kerecis SurgiClose, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PURAPLY WOUND MATRIX, REPATHA, VRAYLAR, Wegovy, YUPELRI, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error